| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Avista Public Acquisition Corp. II | Executive Vice President | No securities beneficially owned | 0 | 09 Aug 2021 | Direct | ||
| RVL Pharmaceuticals plc | Director, 10%+ Owner | Ordinary Shares | 0 | $0.0312 | 27 Jan 2023 | By Avista Capital investment fund |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000110465923008077-venkataraman-sriram-2023-01-27 | RVL Pharmaceuticals plc | 27 Jan 2023 | 1 | $0 | 4 | Director, 10%+ Owner | 30 Jan 2023, 16:28 |
| /report/000110465922088030-venkataraman-sriram-2022-08-08 | RVL Pharmaceuticals plc | 08 Aug 2022 | 1 | +$12,400,000 | 4 | Director, 10%+ Owner | 09 Aug 2022, 17:19 |
| OABI | Avista Public Acquisition Corp. II | 09 Aug 2021 | 0 | $0 | 3 | Executive Vice President | 09 Aug 2021, 21:59 |